<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39375723</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 RNAemia as a reliable predictor of long-term mortality among older adults hospitalized in pulmonary intermediate care units: a prospective cohort study.</ArticleTitle><Pagination><StartPage>247</StartPage><MedlinePgn>247</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">247</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-024-02526-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">SARS-CoV-2 viremia is associated with disease severity and high risk for in-hospital mortality. However, the impact of SARS-CoV-2 viremia on long-term outcomes in hospitalized patients with COVID-19 is poorly understood.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a prospective cohort study and recruited a group of older adult patients with COVID-19 admitted to pulmonary intermediate care units of Peking University Third Hospital during December 2022 and January 2023. The plasma level of SARS-CoV-2 RNA was determined by a standardized RT-PCR technique, and SARS-CoV-2 RNAemia was defined as a plasma viral load ≥ 50 copies/ml. In-hospital and follow-up (180-day) outcome data were collected.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 101 patients with an average of 80.4 years were recruited, and 63.4% of them were severe or very severe cases. Twenty-eight patients (27.7%) had SARS-CoV-2 RNAemia, with a median viral RNA load of 422.1 [261.3, 1085.6] copies/ml. Patients with SARS-CoV-2 RNAemia were more likely to develop critical cases and had a higher incidence of sepsis. Accordingly, they had a higher 180-day mortality (57.1% vs. 19.7%, P &lt; 0.001), as well as in-hospital mortality (50.0% vs. 13.7%, P &lt; 0.001), independent of age, disease severity, sepsis, lymphocyte count and C-Reactive protein. In addition, the risk for 180-day mortality increased with the SARS-CoV-2 RNA load in plasma. Plasma cytokines, including IL-6, IL-8 and IL-10, were higher in patients with SARS-CoV-2 RNAemia.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study indicates that SARS-CoV-2 RNAemia serves as a useful biomarker for predicting mortality, especially long-term mortality, in older adult patients hospitalized in pulmonary intermediate care units.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Chinese Clinical Trial Registry website (No. ChiCTR2300067434).</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, North Garden Rd. 49, Haidian District, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chun</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, North Garden Rd. 49, Haidian District, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Yanling</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, North Garden Rd. 49, Haidian District, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gai</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, North Garden Rd. 49, Haidian District, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Hongling</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Qingtao</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, North Garden Rd. 49, Haidian District, Beijing, 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yongchang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, North Garden Rd. 49, Haidian District, Beijing, 100191, China. suny@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>H82499-03</GrantID><Agency>Peking University Third Hospital-MatriDx Biotechnology Joint Research &amp; Development Center of Molecular Diagnostics</Agency><Country /></Grant><Grant><GrantID>H63512-19</GrantID><Agency>Peking University Third Hospital-MatriDx Biotechnology Joint Research &amp; Development Center of Molecular Diagnostics</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="Y">RNA, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="N">Viremia</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">RNAemia</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Viremia</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>8</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>23</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39375723</ArticleId><ArticleId IdType="pmc">PMC11457408</ArticleId><ArticleId IdType="doi">10.1186/s12985-024-02526-4</ArticleId><ArticleId IdType="pii">10.1186/s12985-024-02526-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nat Commun. 2020;11:5493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603483</ArticleId><ArticleId IdType="pubmed">33127906</ArticleId></ArticleIdList></Reference><Reference><Citation>Colagrossi L, Antonello M, Renica S, Merli M, Matarazzo E, Travi G, et al. SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study. BMC Infect Dis. 2021;21:184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887543</ArticleId><ArticleId IdType="pubmed">33596855</ArticleId></ArticleIdList></Reference><Reference><Citation>Myhre PL, Prebensen C, Jonassen CM, Berdal JE, Omland T. SARS-CoV-2 viremia is associated with inflammatory, but not cardiovascular biomarkers, in patients hospitalized for COVID-19. J Am Heart Assoc. 2021;10: e019756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8200723</ArticleId><ArticleId IdType="pubmed">33596668</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi HK, Weber B, Zhou G, Regan J, Fajnzylber J, Coxen K, et al. Increased prevalence of myocardial injury in patients with SARS-CoV-2 viremia. Am J Med. 2021;134:542–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654293</ArticleId><ArticleId IdType="pubmed">33181107</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardeñoso Domingo L, Roy Vallejo E, Zurita Cruz ND, Chicot Llano M, Ávalos Pérez-Urria E, Barrios A, et al. Relevant SARS-CoV-2 viremia is associated with COVID-19 severity: Prospective cohort study and validation cohort. J Med Virol. 2022;94:5260–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349374</ArticleId><ArticleId IdType="pubmed">35811284</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasuji H, Morinaga Y, Tani H, Yoshida Y, Takegoshi Y, Kaneda M, et al. SARS-CoV-2 RNAemia with a higher nasopharyngeal viral load is strongly associated with disease severity and mortality in patients with COVID-19. J Med Virol. 2022;94:147–53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8426802</ArticleId><ArticleId IdType="pubmed">34411312</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodríguez-Serrano DA, Roy-Vallejo E, Zurita Cruz ND, Martín Ramírez A, Rodríguez-García SC, Arevalillo-Fernández N, et al. Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients. Sci Rep. 2021;11:13134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222315</ArticleId><ArticleId IdType="pubmed">34162948</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JL, Bain W, Naqvi A, Staines B, Castanha P, Yang H, et al. Severe acute respiratory syndrome coronavirus 2 viremia is associated with coronavirus disease 2019 severity and predicts clinical outcomes. Clin Infect Dis. 2022;74:1525–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9070832</ArticleId><ArticleId IdType="pubmed">34374761</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli A, Righini E, Micheli V, Pinoli P, Bernasconi A, Rizzo A, et al. SARS-CoV-2 viremia and COVID-19 mortality: a prospective observational study. PLoS ONE. 2023;18: e0281052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10146509</ArticleId><ArticleId IdType="pubmed">37115764</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C, Li S, Liang Y, Chen M, Liu J. SARS-CoV-2 viremia may predict rapid deterioration of COVID-19 patients. Braz J Infect Dis. 2020;24:565–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492058</ArticleId><ArticleId IdType="pubmed">32950458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagman K, Hedenstierna M, Rudling J, Gille-Johnson P, Hammas B, Grabbe M, et al. Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study. Diagn Microbiol Infect Dis. 2022;102: 115595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595972</ArticleId><ArticleId IdType="pubmed">34896666</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurita-Cruz ND, Martín-Ramírez A, Rodríguez-Serrano DA, González-Álvaro I, Roy-Vallejo E, De la Cámara R, et al. Usefulness of real-time RT-PCR to understand the kinetics of SARS-CoV-2 in blood: a prospective study. J Clin Virol. 2022;152: 105166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9040491</ArticleId><ArticleId IdType="pubmed">35594784</ArticleId></ArticleIdList></Reference><Reference><Citation>Michot JM, Hueso T, Ibrahimi N, Pommeret F, Willekens C, Colomba E, et al. Severe COVID-19 in patients with hematological cancers presenting with viremia. Ann Oncol. 2021;32:1297–300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8275471</ArticleId><ArticleId IdType="pubmed">34265373</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosgurin O, Leidi A, Farhoumand PD, Carballo S, Adler D, Reny JL, et al. Role of intermediate care unit admission and noninvasive respiratory support during the COVID-19 pandemic: a retrospective cohort study. Respiration. 2021;100:786–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8247832</ArticleId><ArticleId IdType="pubmed">34023830</ArticleId></ArticleIdList></Reference><Reference><Citation>Renda T, Scala R, Corrado A, Ambrosino N, Vaghi A. Adult pulmonary intensive and intermediate care units: the Italian Thoracic Society (ITS-AIPO) position paper. Respiration. 2021;100:1027–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">34102641</ArticleId></ArticleIdList></Reference><Reference><Citation>National Health Commission of the People's Republic of China. Diagnosis and treatment protocol for coronavirus disease 2019, trial version 10, 2023. Available from: http://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a/files/02ec13aadff048ffae227593a6363ee8.pdf</Citation></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Schneider AM, Mehta A, Sade-Feldman M, Kays KR, Gentili M, et al. SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. J Clin Invest. 2021;131: e148635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245177</ArticleId><ArticleId IdType="pubmed">34196300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Gao C, Zhao K, Yang Y, Rassadkina Y, Fajnzylber J, et al. Immune-profiling of SARS-CoV-2 viremic patients reveals dysregulated innate immune responses. Front Immunol. 2022;13: 984553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9682031</ArticleId><ArticleId IdType="pubmed">36439166</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C, Li Y, Kaplonek P, Gentili M, Fischinger S, Bowman KA, et al. The kinetics of SARS-CoV-2 antibody development is associated with clearance of RNAemia. MBio. 2022;13: e0157722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426503</ArticleId><ArticleId IdType="pubmed">35762593</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrau L, Frere JJ, Golynker I, Fajardo A, Rivera CF, Horiuchi S, et al. Delayed engagement of host defenses enables SARS-CoV-2 viremia and productive infection of distal organs in the hamster model of COVID-19. Sci Signal. 2023;16:eadg5470.</Citation><ArticleIdList><ArticleId IdType="pubmed">37311033</ArticleId></ArticleIdList></Reference><Reference><Citation>Herminghaus A, Osuchowski MF. How sepsis parallels and differs from COVID-19. EBioMedicine. 2022;86: 104355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9718536</ArticleId><ArticleId IdType="pubmed">36470836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostakis I, Smith GB, Prytherch D, Meredith P, Price C, Chauhan A. The performance of the National Early Warning Score and National Early Warning Score 2 in hospitalised patients infected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Resuscitation. 2021;159:150–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7648887</ArticleId><ArticleId IdType="pubmed">33176170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlström B, Frithiof R, Larsson IM, Strandberg G, Lipcsey M, Hultström M. A comparison of impact of comorbidities and demographics on 60-day mortality in ICU patients with COVID-19, sepsis and acute respiratory distress syndrome. Sci Rep. 2022;12:15703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9487845</ArticleId><ArticleId IdType="pubmed">36127433</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z, Peng Y, Wu X, Pang B, Yang F, Zheng W, et al. Comorbidities and complications of COVID-19 associated with disease severity, progression, and mortality in China with centralized isolation and hospitalization: A systematic review and meta-analysis. Front Public Health. 2022;10: 923485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9424916</ArticleId><ArticleId IdType="pubmed">36052001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalueza A, Lora-Tamayo J, Maestro-de la Calle G, Folgueira D, Arrieta E, de Miguel-Campo B, et al. A predictive score at admission for respiratory failure among hospitalized patients with confirmed 2019 Coronavirus Disease: a simple tool for a complex problem. Intern Emerg Med. 2022;17:515–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082224</ArticleId><ArticleId IdType="pubmed">33914228</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandenburg K, Ferrer-Espada R, Martinez-de-Tejada G, Nehls C, Fukuoka S, Mauss K, et al. A Comparison between SARS-CoV-2 and Gram-Negative Bacteria-Induced Hyperinflammation and Sepsis. Int J Mol Sci. 2023;24:15169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10607443</ArticleId><ArticleId IdType="pubmed">37894850</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036-45.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:ead4570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YM, Shin EC. Type I and III interferon responses in SARS-CoV-2 infection. Exp Mol Med. 2021;53:750–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099704</ArticleId><ArticleId IdType="pubmed">33953323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>